Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Collaboration › Details

Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products

 

Period Period 2016-09-28
  Predecessor ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures
  Successor ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m
Organisations Partner, 1st Boehringer Ingelheim (Group)
  Partner, 2nd ViraTherapeutics GmbH (ViraT)
  Group Boehringer Ingelheim (Group)
Products Product VSV platform (vesicular stomatitis virus platform)
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
     

   
Record changed: 2022-11-19

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top